Recent News

• 06.10.2025 - argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
• 06.10.2025 - argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
• 06.03.2025 - argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
• 06.03.2025 - argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
• 05.28.2025 - argenx Announces Results of Annual General Meeting of Shareholders
• 05.28.2025 - argenx Announces Results of Annual General Meeting of Shareholders
• 05.08.2025 - argenx Reports First Quarter 2025 Financial Results and Provides Business Update
• 05.08.2025 - argenx Reports First Quarter 2025 Financial Results and Provides Business Update
• 05.06.2025 - argenx to Present at BofA Securities 2025 Health Care Conference
• 05.06.2025 - argenx to Present at BofA Securities 2025 Health Care Conference

Recent Filings

• 05.28.2025 - EX-99.1 EX-99.1
• 05.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.08.2025 - EX-99.1 EX-99.1
• 05.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.28.2025 - EX-99.1 EX-99.1